Julia L Clennell
Overview
Explore the profile of Julia L Clennell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
143
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rugo H, Campbell M, Yau C, Jo Chien A, Wallace A, Isaacs C, et al.
Breast Cancer Res Treat
. 2024 Dec;
209(3):487-492.
PMID: 39625569
Purpose: We investigated the small-molecule receptor tyrosine kinase-inhibitor of colony-stimulating factor-1 receptor pexidartinib in the stage II/III breast cancer in the I-SPY2 platform trial. Methods: I-SPY2 is an adaptive platform...
2.
Albain K, Yau C, Petricoin E, Wolf D, Lang J, Jo Chien A, et al.
Clin Cancer Res
. 2023 Dec;
30(4):729-740.
PMID: 38109213
Purpose: The neutralizing peptibody trebananib prevents angiopoietin-1 and angiopoietin-2 from binding with Tie2 receptors, inhibiting angiogenesis and proliferation. Trebananib was combined with paclitaxel±trastuzumab in the I-SPY2 breast cancer trial. Patients...
3.
Lang J, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, et al.
NPJ Breast Cancer
. 2022 Dec;
8(1):128.
PMID: 36456573
HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with...
4.
Clark A, Yau C, Wolf D, Petricoin E, J van t Veer L, Yee D, et al.
Nat Commun
. 2021 Nov;
12(1):6428.
PMID: 34741023
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast...
5.
Yee D, Isaacs C, Wolf D, Yau C, Haluska P, Giridhar K, et al.
NPJ Breast Cancer
. 2021 Oct;
7(1):131.
PMID: 34611148
I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab...
6.
Yee D, DeMichele A, Yau C, Isaacs C, Fraser Symmans W, Albain K, et al.
JAMA Oncol
. 2020 Jul;
6(9):1355-1362.
PMID: 32701140
Importance: Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a...